Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07576699

CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)

The purpose of this study is to determine the efficacy and safety of CK0802 Tregs for treatment of refractory GVHD (graft-versus-host disease)

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Steroid Refractory Graft Versus Host Disease Graft vs Host Disease Immune System Diseases

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

About this study

This clinical trial will be conducted in two parts where the first part of Phase 1b will determine the safety and tolerability of CK0802 in patients with steroid refractory GVHD and the second part of Phase 2a will examine the preliminary efficacy of CK0802 in patients with steroid refractory GVHD

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Age ≥12 years old (first 3 subjects will be ≥ 18 years)
  • 2. Grade 2-4 acute GVHD (aGVHD) at baseline
  • 3. No other prior aGVHD treatment
  • 4. Steroid Refractory
  • Progressed after 3 days of treatment with 2 mg/kg methylprednisolone (MPE)
  • No improvement after 7 days of treatment with 2 mg/kg MPE
  • Progressed to a new organ after treatment with 1 mg/kg MPE for skin or upper gastrointestinal (UGI) aGVHD
  • Progressed from nadir during or after a steroid taper
  • 5. Female subjects of childbearing potential (FPCP) must have a negative urine or serum pregnancy test.
  • 6. Agreed to abide by all protocol required procedures including study-related assessments, visits and long term follow up.
  • 7. Willing and able to provide written informed consent.
  • 8. Signed informed consent

Exclusion criteria

  • 1. 30 days prior treatment with any other investigational agent after allogeneic HSCT.
  • 2. Known HIV seropositivity.
  • 3. Uncontrolled infection, not responding to appropriate antimicrobial agents after seven days of therapy. The Protocol PI is the final arbiter of eligibility.
  • 4. Subjects with uncontrolled inter-current illness that in the opinion of the investigator would place the subject at greater risk of severe toxicity and/or impair the activity of CK0802.
  • 5. Subjects who are pregnant or breastfeeding.

Treatment and study plan

CK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched)

Biological

Subjects will receive seven planned doses of CK0802 on study day +1, +3 (+/-1 day), +5 (+/-1 day), +7 (+/- 2 day), +14 (+/- 3 days), +21 (+/-3 days) and +28 (+/-3 days). A total of 7 doses will be administered.

If Day 29 assessment shows PR or MR, then 4 additional weekly infusion of CK0802 Tregs can be administered (study days: 35 (+/- 2 day), 42 (+/- 2 day), 49 (+/- 2 day), and 55(+/- 2 day)), for a total of 11 infusions

Primary outcomes

  1. Phase 1b

    Time frame: Day +29

    Dose limiting toxicities of CK0802 in SR GVHD as assessed by the incidence and severity of AE and SAEs determined by the NCI-CTCAE Version 6.0.

    Non-Hematologic: Any ≥ Grade 3 non-hematologic AE as per CTCAE v6.0 Hematologic: Any new or worsened Grade 4 neutropenia, thrombocytopenia, or anemia compared with baseline that persists for >7 days despite supportive care and is not clearly and incontrovertibly attributable to the underlying disease or another extraneous cause.

    Death: Death within 28 days that is not clearly and incontrovertibly attributable to the underlying disease or another extraneous cause

  2. Phase 2a

    Time frame: D +29

    Overall Response (OR) at day +29. Overall response (OR) will include complete response (CR) and partial response (PR). Response to be determined from the maximum acute GVHD stage and grade in each organ.

    Complete Response (CR): Stage 0 in all organs (skin, liver, and GI tract) and no intervening additional therapy Partial Response (PR): Improvement of at least 1 stage in 1 or more organs without progression in other organs, and no intervening additional therapy Overall Response (OR): Includes both CR and PR Very Good PR (VGPR): Improvement by at least one stage in one or more organs and

    • Skin: No rash, or bullae, and residual erythematous rash involving <25% of the body surface
    • Liver: Total serum bilirubin concentration of <2 mg/dL or <25% of baseline at enrollment
    • Gut: Tolerating food or enteral feeding, predominantly formed stools, no overt GI bleeding or abdominal cramping, no more than occasional nausea or vomiting
    • No intervening additional therapy

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Trial Specialist

CONTACT

[email protected]

8002178247

Sponsors and collaborators

Lead sponsor

Cellenkos, Inc.

Industry

Registry information

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
May 8, 2026
Registry last updated
May 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.